Sign in
VRCA Stock Price, Chart, Stats & News
Verrica Pharmaceuticals Inc.
Save
61.78M
Market cap
–
Current P/E
–
Forward P/E
VRCA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 90.80% |
Operating margin | -33.56% |
Pretax margin | -50.27% |
Net margin | -50.27% |
Effective tax rate | – |
ROA | -37.95% |
ROE | 252.30% |
D/E | 0.07x |
Interest coverage ratio | -1.54x |
VRCA valuation
P/E | – |
P/S | 1.31x |
P/B | 1.89x |
P/CF | -2.65x |
P/FCF | -2.65x |
P/OCF | -2.65x |
PEG | -0.05x |
EV multiple | -6.74x |
About
Verrica Pharmaceuticals Inc. is a US-based pharmaceutical company dedicated to developing and commercializing therapeutic solutions for various skin diseases. Its primary investigational compound, VP-102, has successfully completed Phase II clinical trials for molluscum contagiosum and external genital warts, and is presently in Phase II development for common warts. Additionally, the company is advancing VP-103, a cantharidin-based product candidate, designed to treat plantar warts.
Similar securities
Based on sector and market capitalization
Report issue